GMH (Menopur)75 IU HMG

Adverse effects and incidences may vary according to specific product, indication, dosage, or route of administration.

>10%: Genitourinary: Multiple gestation (35%)

1% to 10%:

Central nervous system: Headache (5% to 6%)

Endocrine & metabolic: Ovarian disease (3% to 8%), ovarian hyperstimulation syndrome (2% to 7%)

Gastrointestinal: Abdominal pain (5% to 7%), nausea (4% to 7%), abdominal cramps (3% to 7%), enlargement of abdomen (2% to 6%), gastrointestinal fullness (?5%), vomiting (3%), diarrhea (2%)

Genitourinary: Vaginal hemorrhage (3% to 8%), pelvic pain (1% to 3%), breast tenderness (2%), ectopic pregnancy (1%)

Infection: Infection (1%)

Local: Injection site reaction (2% to 8%), swelling at injection site (1% to 8%), pain at injection site (?4%), inflammation at injection site (2%)

Respiratory: Dyspnea (1% to 2%)

Frequency not defined:

Cardiovascular: Tachycardia

Central nervous system: Dizziness

Dermatologic: Rash at injection site, skin rash

Endocrine & metabolic: Ovarian cyst, ovary enlargement

Hematologic & oncologic: Hemoperitoneum, ovarian neoplasm

Hypersensitivity: Anaphylaxis

Local: Irritation at injection site

Respiratory: Flu-like symptoms, tachypnea

Miscellaneous: Fetal abnormality, ovarian torsion

<1%, postmarketing, and/or case reports: Abdominal distention, abdominal distress, acne vulgaris, acute respiratory distress syndrome, angioedema, atelectasis, cerebrovascular accident, embolism, facial edema, fatigue, hot flash, hypersensitivity reaction, laryngeal edema, local tissue necrosis, lower abdominal pain, malaise, occlusion of cerebral arteries, occlusive arterial disease (may result in loss of limb), pulmonary complications, pulmonary embolism, pulmonary infarct, thromboembolism, thrombophlebitis (includes venous), thrombosis